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Abstract 
Introduction and objectives. Most studies have shown that prognosis of heart failure with preserved systolic function 
is as poor as that of heart failure with depressed systolic function, although these results may be biased by the fact 
that these types of heart failure have different characteristics (age, comorbidity, treatment), which can influence 
prognosis. Our aim was to determine whether short-term morbidity and mortality differed in these 2 subgroups of 
heart failure patients when they were comparable in terms of age, associated comorbidity, and therapy. 
Methods. We analyzed 2 groups of patients aged >70 years who were candidates to receive beta blockers (preserved 
systolic function, 245; depressed systolic function, 374), consecutively discharged from 53 participating Spanish 
hospitals with a diagnosis of heart failure, and compared cardiovascular morbidity and mortality 3 months after 
discharge. 
Results. Mean age was similar (77.5 ± 4.8 vs 78.2 ± 5.5 years). Left ventricular ejection fraction was 56.2% ± 8.1% 
vs 33% ± 6.9% (P<.001). The combined event rate (death, hospitalization for heart failure, acute coronary syndrome, 
or stroke) at 3 months after discharge was lower in patients with heart failure and preserved systolic function (13.4% 
vs 20.6%; P=.026). Depressed systolic function was an independent predictor of greater incidence of events (odds 
ratio=1.732; P=.048). 
Conclusions. In patients of similar age and receiving similar treatment, short-term prognosis is better in patients with 
heart failure and preserved systolic function than in those with depressed systolic function. 
Resumen 
Introducción y objetivos. La mayoría de los trabajos han puesto de manifiesto que el pronóstico de la insuficiencia 
cardiaca con función sistólica conservada es tan malo como el de la insuficiencia cardiaca con función sistólica 
deprimida, aunque estos resultados pueden estar sesgados debido a que estos dos tipos de insuficiencia cardiaca 
tienen características distintas (edad, comorbilidades, tratamiento) que pueden influir en el pronóstico. Nuestro 
objetivo es evaluar si la morbimortalidad a corto plazo es distinta en estos dos subgrupos de insuficiencia cardiaca, 
con pacientes homogéneos en cuanto a edad, comorbilidad y tratamiento recibido. 
Métodos. Analizamos dos grupos de pacientes mayores de 70 años y que pudieran recibir bloqueadores beta, dados de 
alta consecutivamente tras un ingreso por insuficiencia cardiaca en 53 hospitales españoles (función sistólica 
deprimida, 245; función sistólica conservada, 374), y se comparó la morbimortalidad cardiovascular a los 3 meses del 
alta. 
Resultados. Las medias de edad fueron similares (77,5 ± 4,8 frente a 78,2 ± 5,5 años). La fracción de eyección 
ventricular izquierda fue de 56,2 ± 8,1% frente a 33 ± 6,9% (p < 0,001). La incidencia del evento combinado (muerte, 
ingreso por insuficiencia cardiaca, síndrome coronario agudo o ictus) a los 3 meses del alta fue menor en los 
pacientes con insuficiencia cardiaca y función sistólica conservada (el 13,4 frente al 20,6%; p = 0,026). Tener la 
función sistólica deprimida fue predictor independiente de mayor incidencia de eventos (odds ratio = 1,732; 
p = 0,048). 
Conclusiones. En pacientes de edad similar que reciben el mismo tratamiento, el pronóstico a corto plazo es mejor en 
los pacientes con insuficiencia cardiaca y función sistólica conservada que en aquellos con función sistólica 
deprimida. 
Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; HF, heart 
failure; LVEF, left ventricular ejection fraction 
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Introduction 
Heart failure (HF) is a clinical syndrome of great relevance due to its high and increasing prevalence1 and 
high levels of morbidity and mortality.2 These problems are aggravated with age as prevalence increases 
exponentially with the years1 and prognosis is worse in older patients.3 and 4 In recent decades, drugs have 
been developed that improve prognosis in HF. These include angiotensin converting enzyme inhibitors 
(ACEI), angiotensin receptor blockers (ARB), antialdosterone drugs, and beta blockers (BB). Their use 
has facilitated improved prognosis in these patients,5 although producing only a mildly favorable effect in 
the general population of patients with HF.2 One reason the effect of this treatment in the general 
population has not been more positive is that–like electrical treatments such as resynchronization or 
implantable defibrillators– these drugs have only proved efficacious in patients with HF and depressed 
systolic function.6 and 7 No evidence exists about their usefulness to improve prognosis in patients with HF 
and preserved systolic function, who represent approximately half of the patients with HF.1 In fact, 
several studies have shown that in recent years mortality in HF with depressed systolic function has 
fallen, but in HF with preserved systolic function it has not.8 and 9 Moreover, the accepted view that low 
left ventricular ejection fraction (LVEF) was a factor indicating poor prognosis in patients with HF has 
been changed by numerous studies conducted in Spain and elsewhere10, 11, 12, 13, 14 and 15 that have shown 
prognosis was equally poor in patients with preserved LVEF or depressed LVEF. 
However, factors other than LVEF itself may influence these results. The characteristics of HF 
patients with preserved systolic function differ from those of patients with depressed systolic function or 
depressed LVEF (they are older and have more comorbidities, more of them are women, they have 
different etiologies and receive different treatments),10, 11, 12, 13, 14, 15 and 16 and some of these differences, 
such as greater age, associated comorbidity, or less drug treatment, may unfavorably bias the final result. 
The objective of our study is to determine whether short-term morbidity and mortality differ in these 2 
types of HF, when analyzing groups of patients in terms of age, comorbidity, and treatment received. 
Methods 
To achieve our objective, we conducted a subanalysis of the recently published OBELICA study.17 This 
study, conducted in 2007-2008, included 627 men and women aged ≥70 years and diagnosed with HF 
according to European Cardiology Society criteria,7 independently of LVEF. Given that the main variable 
indicating efficacy in this study was the percentage of patients receiving the optimal dosage of BB at 3-
month follow-up, the patients included should present no contraindications to BB use. The study was 
coordinated and overseen by the Spanish Society of Cardiology research agency, and conducted thanks to 
an unconditional grant from Menarini. Fifty-three hospitals in autonomous regional communities 
throughout Spain participated in the study (11 in Andalusia, 2 in the Principality of Asturias, 2 in the 
Balearic Islands, 7 in Valencian Community, 4 in the Canary Islands, 3 in Castile-La Mancha, 4 in Castile 
and León, 7 in Catalonia, 2 in Extremadura, 3 in Galicia, 5 in the Community of Madrid, and 3 in the 
Basque Country). Each center included 14 patients consecutively discharged following hospitalization for 
a principle diagnosis of HF. We defined HF with preserved systolic function as >45% LVEF and HF with 
depressed systolic function as ≤45% LVEF. At 3 months, we reviewed all patients in cardiology or HF 
clinics. At each visit we collected demographic, clinical, and treatment data (Table 1, Table 2 and Table 
3). At the final visit, at 3 months, we also collected data on events since enrollment. Nine patients were 
lost to follow-up, leaving 618 whose data were included in the final analysis. The principle variable in 
this subanalysis was the combined outcome of overall mortality and hospitalization for cardiovascular 
cause (HF, myocardial infarction, unstable angina, stroke, arrhythmias) during the 3-month follow-up. All 
events were verified by consulting patient clinical case histories for in-hospital cases and by personal or 
telephone contact with the primary care physician and/or family of patients who died out-of-hospital. The 
study was approved by the clinical research ethics committee (Hospital General de Alicante) and 
complied with Spanish legislation on clinical trials. Participants were required to give written informed 
consent.  
Table 1. Characteristics of Patients With Heart Failure and Preserved or Depressed Systolic Function at First Visit. 
 PSF (n=246) DSF (n=372) P 
    
Age, years 78.2±5.5 77.5±4.8 .101 
Women 130 (52.8) 125 (33.6) <.001 
Previous admission for HF 97 (39.4) 231 (62.1) <.001 
High blood pressure 204 (82.9) 267 (71.7) .001 
Diabetes mellitus 91 (36.9) 153 (41.1) .316 
Hypercholesterolemia 96 (39) 190 (51.1) .004 
Myocardial infarction 65 (26.4) 193 (51.9) <.001 
COPD 34 (13.8) 61 (16.4) .412 
Anemia 58 (23.6) 97 (26.1) .478 
Stroke 26 (10.6) 38 (10.2) .857 
Smoker 82 (33.3) 186 (50) <.001 
Previous coronary revascularization 42 (17.1) 109 (29.3) .002 
Functional class   .052 
 I 24 (9.8) 31 (8.3)  
 II 121 (49.2) 147 (39.5)  
 III 97 (39.4) 183 (49.2)  
 IV 4 (1.6) 11 (3)  
Etiology of HF   <.001 
 Ischemic 68 (27.7) 231 (62.1)  
 Hypertensive 156 (63.4) 44 (11.8)  
 Idiopathic dilated cardiomyopathy 0 79 (21.2)  
 Valvular heart disease 15 (6.1) 11 (3)  
 Other 7 (2.8) 7 (1.9)  
Systolic blood pressure, mmHg 141±21.2 127.3±19.3 <.001 
Diastolic blood pressure, mmHg 78.4±14 74.6±11.6 <.001 
Body mass index 28.9±4.4 27.3±3.8 <.001 
Atrial fibrillation; 91 (37) 122 (32.8) .278 
Ejection fraction, % 56.2±8.1 33±6.9 <.001 
    
 
COPD, chronic obstructive pulmonary disease; DSF, depressed systolic function; HF, heart failure; PSF, preserved systolic 
function. 
Means are compared using Student's t test or the Wilcoxon test for 2 independent samples; proportional homogeneity, using chi-
squared. 
Results are expressed as n (%) (for qualitative variables) and mean±standard deviation (for continuous variables). 
Table 2. Biochemical Parameters for Patients With Heart Failure and Preserved or Depressed Systolic Function at First Visit. 
 PSF (n=246) DSF (n=372) P 
    
Hemoglobin, g/l 12.9±1.8 12.6±1.8 .268 
BNP, pg/ml 320.9±398.8 458.6±233.8 .108 
Creatinine, mg/dl 1.2±0.6 1.3±0.6 .127 
Sodium, mEq/l 139.27±3.4 139±3.6 .234 
Potassium, mEq/l 4.4±0.5 4.5±0.5 .078 
    
 
BNP, brain natriuretic peptide; DSF, depressed systolic function; PSF, preserved systolic function. 
Means are compared with Student's t test or the Wilcoxon test for 2 independent samples. 
Results are expressed as mean ± standard deviation. 
  
Table 3. Drug Treatment of Patients With Heart Failure and Preserved or Depressed Systolic Function at First Visit and at Final 
Visit 3 Months After Discharge. 
 PSF DSF P 
    
First visit    
 Patients 246 372  
 ACEI/ARB 214 (87) 337 (90.6) .074 
 Digitalis 49 (20) 101 (27.2) .039 
 Beta blockers 211 (85.8) 331 (89) .169 
 Statins 113 (46) 229 (61.6) <.001 
 Anticoagulants 99 (40.2) 154 (41.4) .798 
 Antiplatelet drugs 114 (46.3) 211 (56.7) .013 
 Diuretics 208 (84.5) 334 (89.8) .057 
 Antialdosterone drugs 47 (19.1) 169 (45.4) <.001 
Final visit    
 Patients 243 358  
 ACEI/ARB 217 (89.3) 326 (91.1) .471 
 Digitalis 48 (19.7) 88 (24.6) .163 
 Betablockers 214 (88.1) 330 (92.2) .094 
 Statins 122 (50.2) 226 (63.1) <.001 
 Anticoagulants 98 (40.3) 148 (41.3) .798 
 Antiplatelet drugs 108 (44.45) 205 (57.3) .010 
 Diuretics 191 (78.6) 314 (87.7) .004 
 Antialdosterone drugs 45 (18.5) 162 (45.2) <.001 
    
 
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; DSF, depressed systolic function; PSF, 
preserved systolic function. 
Proportional homogeneity is compared with chi-squared. 
Results are expressed as n (%). 
Statistical Analysis 
In 2 groups of patients with HF and preserved or depressed systolic function, we compared baseline 
characteristics and events at 3-month follow-up using chi-squared for qualitative variables and Student's t 
test or the Wilcoxon test for continuous variables. A value of P<.05 was considered statistically 
significant. We also performed stepwise logistic regression multivariate analysis to determine those 
factors independently associated with a greater rate of events at 3 months. This model included all 
variables showing statistical significance in univariate analysis ( Table 4) and other clinically relevant 
parameters (history of high blood pressure, diabetes mellitus, HF etiology, treatment with ACEI, BB and 
antialdosterone drugs) that showed no significant differences in the univariate study. 
  
Table 4. Comparison of Patient Characteristics at First Visit Between Groups With and Without Events During the 3-month Follow-
up. 
 Cardiovascular event 
P 
 No (n=508) Yes (n=110) 
    
Age, years 77.4±5 79.3±5.2 <.001 
Women 200 (39.3) 54 (49.1) .017 
Clinical course of HF in months 29.5±36.7 38.8±46.9 .065 
Previous admissions for HF 251 (49.4) 77 (70.2) <.001 
High blood pressure 389 (76.6) 82 (74.5) .513 
Diabetes 200 (39.3) 44 (40) .965 
Hypercholesterolemia 243 (47.8) 43 (39.1) .281 
Myocardial infarction 200 (39.3) 58 (52.7) .018 
COPD 75 (14.7) 20 (18.2) .746 
Anemia 120 (23.6) 35 (31.8) .032 
Stroke 50 (9.8) 14 (12.7) .202 
Smoker 226 (44.5) 42 (38.2) .079 
Previous coronary revascularization 118 (23.2) 33 (30) .133 
Functional class   <.001 
 I-II 290 (57.1) 33 (30)  
 III-IV 218 (42.9) 77 (70)  
Etiology of HF    
 Ischemic 244 (48) 55 (50) .450 
 Hypertensive 172 (33.8) 28 (25.5) .139 
 Other 92 (18.2) 27 (24.5) .782 
Systolic blood pressure, mmHg 133.8±21.3 127.7±19.9 .006 
Diastolic blood pressure, mmHg 75.9±12.8 74.1±12.5 .199 
Heart rate, bpm 77.3±16.7 76.9±16 .801 
Body mass index 28.1±4.2 27.3±3.9 .087 
Atrial fibrillation 163 (32) 50 (45.5) .046 
Ejection fraction, % 47.5±13.6 39.3±12.3 .023 
HF with preserved systolic function 213 (41.9) 33 (30) .026 
Hemoglobin, g/l 12.8±1.8 12.3±1.9 .015 
BNP, pg/ml 404.2±326.1 426.9±234.8 .463 
Creatinine, mg/dl 1.2±0.6 1.5±0.8 .007 
Sodium, mEq/l 139.4±3.4 138.5±4.4 .047 
Potassium, mEq/l 4.4±0.5 4.5±0.5 .213 
Treatment    
 ACEI/ARB 455 (89.6) 96 (87.3) .126 
 Digitalis 122 (24) 28 (25.4) .894 
 Beta blockers 446 (87.8) 96 (87.2) .568 
 Anticoagulants 196 (38.6) 57 (51.8) .036 
 Antiplatelet drugs 268 (52.8) 57 (51.8) .929 
 Diuretics 437 (86) 105 (95.4) .011 
 Antialdosterone drugs 178 (35) 38 (34.6) .759 
    
 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; BNP, brain natriuretic peptide; COPD, 
chronic obstructive pulmonary disease; HF, heart failure. 
Means are compared with Student's t test or the Wilcoxon test for 2 independent samples; proportional homogeneity is compared 
with chi-squared. Results are expressed as n (%) (for qualitative variables) and mean ± standard deviation (for continuous variables). 
Results 
Baseline Characteristics of Groups 
We enrolled 627 patients; 40% (n=250) with preserved systolic function and 60% (n=377) with depressed 
systolic function. Nine patients were lost during follow-up: 4 with preserved systolic function and 5 with 
depressed systolic function. Hence our analysis included data on 618 patients (246 in the first group and 
372 in the second). Clinical characteristics during hospitalization and the most important aspects of 
clinical history are in Table 1. In both groups, mean age was similar at ±78 years. The group with HF and 
preserved systolic function included a higher percentage of women (52.7% vs 33.7%; P<.001). Previous 
admission for HF was recorded in 62% of patients with depressed systolic function and 39.6% of patients 
with preserved systolic function (P<.001). Prevalence of high blood pressure was greater in patients with 
preserved systolic function; prevalence of hyperlipidemia, smoking, myocardial infarction, and coronary 
revascularization was greater among those with depressed systolic function ( Table 1). Prevalence of 
atrial fibrillation, diabetes mellitus, chronic obstructive pulmonary disease, anemia, and stroke was 
similar in both groups ( Table 1). The most frequent etiology in patients with HF and depressed systolic 
function was ischemic heart disease (62.1%); in patients with HF and preserved systolic function it was 
high blood pressure (63.4%; P<.001) ( Table 1). LVEF was 56.2%±8.1% in the group with preserved 
systolic function and 33%±6.9% in those with depressed systolic function (P<.001). No relevant clinical 
differences were found between groups in biochemical parameters (including brain natriuretic peptide, 
hemoglobin, and serum creatinine) ( Table 2). 
Drug Treatment 
Table 3 shows drug treatments received by patients in both groups at discharge, during the enrollment 
visit, and at 3-month follow-up, on the final visit. The percentages of patients receiving ACEI or ARB, 
diuretics, BB, and anticoagulants were high and similar in both groups. Patients with depressed systolic 
function received proportionately more antiplatelet drugs, statins, antialdosterone drugs, and digitalis 
(Table 3). These results changed little on the visit at 3 months after discharge (Table 3), although the 
percentage of patients taking BB increased slightly in both groups (88.1% in those with preserved systolic 
function and 92.2% in those with depressed systolic function), and the percentage of patients receiving 
diuretics fell, particularly in the group with preserved systolic function (Table 3). No differences were 
found in the percentages of patients reaching the optimal or maximum tolerated dose of BB (39.6% in the 
group with HF and preserved systolic function and 46.8% in the group with HF and depressed systolic 
function; P=.08). Incidence of secondary effects caused by BB was also similar (7.7% vs 10.9%; P=.19). 
Events During Follow-up 
Figure 1 shows mortality and the cardiovascular event rate during the 3-month follow-up in both groups. 
Patients with HF and preserved systolic function presented lower incidence of death and/or 
cardiovascular-cause admission (13.4% vs 20.6%; P=.026). The mortality rate was three times less in this 
group (1.3% vs 3.9%), although this was not statistically significant, probably due to the low number of 
deaths. There were no differences in other events (admissions for decompensation of HF, acute coronary 
syndrome, stroke, and other causes). Days of hospitalization during the 3 months were also similar 
(8.0±5.9 vs 8.7±8.5; P=.412). A greater percentage of patients with HF and preserved systolic function 
were in New York Heart Association (NYHA) functional class I or II at 3-month follow-up (88% vs 74%; 
P<.001). Table 4 compares patients who presented events during the 3-month follow-up and those who 
did not. The proportion of patients with HF and preserved systolic function was greater in the subgroup 
with no events (41.9% vs 30.2%; P=.026). In multivariate logistic regression analysis, HF with depressed 
systolic function was an independent predictor of events at 3 months (odds ratio [OR]=1.732; 95% 
confidence interval, 1.080-3.061; P=.048), as were NYHA functional class III-IV, age, female sex, 
previous myocardial infarction, and prior admission for HF ( Table 5). 
 
 
 
Figure 1. Incidence of events at 3-month follow-up in our patients. ACS, acute coronary syndrome; HF, heart failure; NS, not 
significant. 
  
Table 5. Independent Predictors of Events During 3-month Follow-up. Results of Logistic Regression Analysis. 
Variable OR (95%CI) P 
   
Functional class III-IV 3.295 (1.231-4.235) .024 
Previous myocardial infarction 1.932 (1.183-3.458) .028 
Age 1.060 (1.008-1.114) .021 
Depressed HF 1.732 (1.080-3.061) .048 
Previous admissions for HF 1.786 (1.052-3.032) .031 
Female gender 1.675 (1.013-2.770) .044 
   
 
95%CI, 95% confidence interval; HF, heart failure; OR, odds ratio. 
 
Discussion 
In the last 10 or 15 years, the question of whether the prognosis of patients with HF and preserved 
systolic function was similar to that of patients with HF and depressed systolic function has provoked 
controversy. Although depressed LVEF has traditionally been considered a factor in poor prognosis in 
HF,18 most recent studies,10, 11, 12, 13, 14, 15, 19 and 20 but not all,9 have indicated that prognosis in HF with 
preserved systolic function is similar or equally poor as in HF with depressed systolic function. However, 
these studies also show that demographic, clinical, and treatment characteristics of these 2 groups of 
patients differ, and that some of them can bias the prognosis in one direction or the other. In effect, 
patients with HF and preserved systolic function are older, present greater associated comorbidity, and 
receive proportionately fewer drugs shown to improve prognosis in patients with HF and systolic 
dysfunction, like ACEI, antialdosterone drugs, and BB. These factors can make the prognosis of patients 
with preserved systolic function seem worse than it would be if more homogeneous groups of patients 
were compared. In some of these studies, the prognosis for the 2 HF sub-types does remain similar after 
adjusting for some of these variables, but the most precise analytical approach is to compare 2 groups in 
which potentially confounding variables are equally distributed. The OBELICA study design has enabled 
us to compare 2 wide-ranging groups of patients with HF and preserved or depressed systolic function 
who are all of a similar age–quite old, in fact. Comorbidity rates are also the same, as, by and large, is 
treatment received, with a high proportion–close to 90%-95%–taking ACEI/ARB and BB.17 Only use of 
antialdosterone drugs, statins and antiplatelet drugs was significantly greater in patients with HF and 
depressed systolic function (Table 3). The results of our analysis–even with such a short 3-month follow-
up after admission for decompensation of HF–indicate cardiovascular morbidity and mortality were 
significantly lower in patients with HF and preserved systolic function (13.4% vs 20.6%; Fig. 1). Even 
overall mortality was 3 times less in the group with preserved LVEF (1.2% vs 3.8%), although this was 
not statistically significant, probably due to the low number of deaths associated with the short follow-up. 
At 3 months, functional class was also better in the group with HF and preserved LVEF: 87.6% of 
patients with HF and preserved systolic function and 74.4% of those with HF and depressed systolic 
function (P<.001) were in class I or II. 
In the previously mentioned studies,10, 11, 12, 13, 14, 15, 19 and 20 lower age and less comorbidity in patients 
with systolic dysfunction could have reduced morbidity and mortality in these patients, improving their 
prognosis so that it approached that of patients with preserved LVEF. Our study has not wholly 
eliminated the comorbidity bias as patients with HF and depressed systolic function presented greater 
prevalence of smoking, myocardial infarction, or coronary revascularization. However, we have 
substantially reduced it. Moreover, in the stepwise logistic regression multivariate model, HF with 
depressed systolic function remained an independent predictor of a greater rate of events. Furthermore, 
the percentage of patients receiving ACEI or ARB and, above all, BB, was very high and similar in our 2 
study groups. This contrasts with the findings of most other studies, in which patients with HF and 
depressed systolic function received proportionately more BB. Although there is no evidence from 
controlled clinical trials to show the beneficial effect of these drugs on patients with HF and preserved 
LVEF21 and 22 –hence, probably, they are less frequently used in patients with preserved systolic function–
some non-randomized studies indicate BB use may be associated with improved prognosis in these 
patients.23 and 24 Beta blockers can benefit patients with HF and preserved systolic function, either through 
their negative chronotropic effect or their control of high blood pressure and ischemic heart disease (the 
principle causes of this problem). In the SENIORS study,24 which also included patients with HF and 
preserved systolic function, BB had a similar effect in patients with depressed and preserved LVEF. In 
our study, approximately 90% of patients in both groups received ACEI or ARB and BB, as shown in 
Table 3. 
Limitations 
Our study has certain limitations–principally the short, 3-month follow-up due to the design of the 
original study.17 For the same reason, we excluded from analysis in-hospital deaths prior to discharge. 
However, the rate of events in patients discharged for HF is greater in the first months of follow-up8, 10, 20, 
21 and 22 and progressively falls later, so these data do not affect the validity of our study. The curves of 
events in HF studies would normally be expected to separate gradually over the follow-up period, with 
the initial trend being accentuated. Consequently, the differences we found probably would have been 
greater in a longer follow-up. Another limitation, which we have already discussed, is BB use. We do not 
know their real effect in prognosis of HF with preserved LVEF since no controlled studies have been 
done, but they may well be beneficial.23 and 24 In our study, we eliminated bias due to possible differences 
derived from proportionately different use of these drugs in one or the other group of patients with HF. 
Finally, we only enrolled patients treated in cardiology services and excluded those admitted in internal 
medicine, who usually present greater comorbidity. However, the high mean age of our patients–78 
years–reduces this bias. 
Conclusions 
From our results, it can be concluded that the prognosis of patients with HF and preserved systolic 
function appears better than that of patients with HF and depressed systolic function, at least in the short 
term. When we eliminate potentially confounding factors in patient characteristics that may influence 
prognosis–eg, age, comorbidity, and treatment received–morbidity and mortality are significantly lower 
and the trend in overall mortality is 3 times lower at 3-month follow-up. Studies with these characteristics 
and longer follow-up are needed to confirm these data. 
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